LncRNA BLACAT1 May Serve as a Prognostic Predictor in Cancer: Evidence from a Meta-Analysis

Background. As a newly discovered lncRNA, bladder cancer-associated transcript 1 (BLACAT1) has been reported to correlate with poor clinical outcomes in several different cancers. This study aimed to evaluate its generalized predictive value for cancer prognosis. Materials and Methods. We thoroughly searched PubMed, Embase, and Web of Science databases for eligible studies published until November 11, 2018, in which the relationship between BLACAT1 expression and cancer prognosis was explored. The analyses were performed using Review Manager Version 5.3 and Stata SE 12.0. The primary endpoints included overall survival (OS), pathological characteristics (TNM stage and tumor grade), lymph node metastasis (LNM), and distant metastasis. Results. Ten studies containing 861 patients with 7 different cancerous diseases were eventually included. The results demonstrated that patients with high lncRNA BLACAT1 expression had a significantly shorter OS (HR: 1.82, 95% CI: 1.44-2.30, p < 0.00001) than patients with low lncRNA BLACAT1 expression. Moreover, elevated BLACAT1 expression was significantly associated with advanced TNM stage (OR: 2.29, 95% CI: 1.15-4.56, p = 0.005), high tumor grade (OR: 1.67, 95% CI: 1.11-2.53, p = 0.01), and lymph node metastasis (OR: 2.53, 95% CI: 1.80-3.57, p < 0.00001). Meanwhile, the expression of BLACAT1 had no significant association with age (p = 0.92), gender (p = 0.55), and smoking (p = 0.62). Conclusion. High expression of lncRNA BLACAT1 may predict a poor prognosis in OS, TNM stage, tumor grade, and LNM. Its predictive roles were not significantly affected by age, gender, or smoking. Therefore, lncRNA BLACAT1 may serve as a promising predictor in cancer prognosis.

Download Full-text

LncRNA NORAD as a Novel Predictor of Lymph Node Metastasis and Prognosis in Solid Tumors: A Systematic Review and Meta-Analysis

Technology in Cancer Research & Treatment ◽

10.1177/1533033820963586 ◽

2020 ◽

Vol 19 ◽

pp. 153303382096358

Author(s):

Tao Ye ◽

Zhangqun Ye

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Meta Analysis ◽

Tumor Grade ◽

Node Metastasis ◽

Human Cancers ◽

Non Coding Rna ◽

Relationship Of ◽

The Relationship ◽

Review Manager

Background: Non-coding RNA-activated by DNA damage (NORAD), a novel identified lncRNA, was found to be aberrantly expressed in various types of cancer. This meta-analysis was performed to evaluate the value of lncRNA NORAD as a prognostic biomarker in human cancers. Methods: We searched PubMed, Web of Science, PMC, and Embase databases thoroughly for eligible literatures. Studies which explored the relationship of lncRNA NORAD expression with clinical outcomes in human cancers were included in our meta-analysis. Review Manager version 5.3 and Stata SE 12.0 were used to perform the data analyses. Results: Our meta-analysis results indicated that cancer patients with high lncRNA NORAD expression tended to have unfavorable overall survival (OS) (HR = 1.67; 95% CI, 1.44-1.95; P < 0.00001). Moreover, elevated lncRNA NORAD expression showed a significant relationship with poor tumor grade (OR = 1.61; 95% CI, 1.01-2.56; P = 0.05) and more lymph node metastasis (LNM) (OR = 2.66; 95% CI, 1.60-4.43; P = 0.0002). Conclusions: LncRNA NORAD could serve as a valuable biomarker to predict poor prognosis and LNM in various human tumors.

Download Full-text

Lack of Relationship Between PROX1 Expression and Clinicopathological Parameters and Prognosis in Gastric Cancer Patients: A Meta-analysis and TCGA Analysis

10.21203/rs.3.rs-1003592/v1 ◽

2021 ◽

Author(s):

Zirui Jia ◽

Yuhang Wang ◽

Jiacheng Gao ◽

Guo Zu

Keyword(s):

Gastric Cancer ◽

Overall Survival ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Size ◽

Meta Analysis ◽

Tnm Stage ◽

Node Metastasis ◽

Prox1 Expression ◽

The Relationship

Abstract Background:The relationship between PROX1 expression and clinicopathological characteristics and prognosis in patients with gastric cancer (GC) is hotly contested and continues to be so. The aim of this study is to determine the clinicopathological and prognostic significance of PROX1 expression in patients with GC.Methods:PROX1 expression in GC patients was evaluated clinicopathologically and in terms of overall survival (OS) using a systematic literature search and meta-analysis. Additionally, the Cancer Genome Atlas (TCGA) and The Genotype-Tissue Expression (GTEx) datasets were utilized to examine the relationship between PROX1 expression and clinicopathological significance and overall survival (OS) in GC patients.Results:A total of 8 studies pooling 1289 GC patients were included in the assessment. PROX1 expression, in GC patients, was shown to be unrelated to gender (odds ratio (OR) : 1.234, 95%CI: 0.958-1.590, P = 0.104), depth of tumor invasion (OR: 0.742, 95%CI:0.428-1.287, P = 0.289), lymph node metastasis (OR: 2.161, 95%CI: 0.808-5.779, P = 0.125), TNM stage (OR: 1.324, 95%CI: 0.572-3.066, P = 0.513), tumor size (OR: 0.889, 95%CI: 0.502-1.576, P = 0.687), metastasis (OR: 1.096, 95%CI: 0.470-2.555, P= 0.763), 1-year OS (OR: 0.908, 95%CI: 0.631-1.306, P = 0.602), 3-years OS (OR: 1.234, 95%CI: 0.482-3.160, P = 0.661) and 5-years OS (OR: 0.853, 95%CI: 0.266-2.736, P = 0.790). Patients with high PROX1 expression had a worse OS than those with low PROX1 expression, according to TCGA analyses, however the difference was not statistically significant (p=0.119).Conclusion:The expression of PROX1 was shown to be unrelated to gender, TNM stage, depth of invasion, tumor size, stage, tumor cell metastasis, or lymph node metastasis. The expression of PROX1 was also unrelated to OS and it failed to be a meaningful biomarker to prevent and diagnose GC.

Download Full-text

Prognostic value of low microRNA-34a expression in human gastrointestinal cancer: a systematic review and meta-analysis

BMC Cancer ◽

10.1186/s12885-020-07751-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Yan-Ling Chen ◽

Xiao-Lin Liu ◽

Ling Li

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Meta Analysis ◽

Disease Free Survival ◽

Tnm Stage ◽

Cancer Prognosis ◽

Expression Level ◽

Free Survival ◽

Node Metastasis

Abstract Background Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs). Methods All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs. Results A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52–2.28, P < 0.01). For disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS), lower miR-34a expression was related to worse DFS/PFS/RFS with a pooled HR of 1.86 (95% CI: 1.31–2.63, P < 0.01). A significant relation of differentiation/TNM stage/lymphatic metastasis and the expression level of miR-34a was identified. Conclusion This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs.

Download Full-text

SP1 Expression and the Clinicopathological Features of Tumors: A Meta-Analysis and Bioinformatics Analysis

Pathology & Oncology Research ◽

10.3389/pore.2021.581998 ◽

2021 ◽

Vol 27 ◽

Author(s):

Yue Gao ◽

Kai Gan ◽

Kuangzheng Liu ◽

Bin Xu ◽

Ming Chen

Keyword(s):

Hepatocellular Carcinoma ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Bioinformatics Analysis ◽

Meta Analysis ◽

Tnm Stage ◽

Cochrane Library ◽

Lower Grade ◽

Depth Of Invasion ◽

Node Metastasis

Objective: Specificity protein 1 (SP1) plays a vital role to promote carcinogenesis in a variety of tumors, and its up-regulated expression is reported to be a hinter of poor prognosis of patients. We conducted this meta-analysis to elucidate the clinical significance and prognostic value of SP1 in malignant tumors.Methods: PubMed and Cochrane Library were searched for studies published between January 1, 2000 and June 1, 2020. The combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to investigate the correlation of SP1 with clinical behaviors and prognosis in patients with solid tumors. UALCAN was used to conduct bioinformatics analysis.Results: A total of 24 documents involving 2,739 patients were enrolled in our review. The random-effect model was used to perform this analysis due to the high level of heterogeneity. SP1 low expression was not conducive to lymph node metastasis (OR = 0.42; 95% CI: 0.28-0.64; p < 0.05), progression of TNM stage (OR = 0.34; 95% CI: 0.20-0.57; p < 0.05) and tumor infiltration (OR = 0.33; 95% CI: 0.18-0.60; p < 0.05). Elevated SP1 expression was connected with shorter survival time of patients with hepatocellular carcinoma, pancreatic cancer, gastric cancer and esophageal cancer (HR = 1.95; 95% CI: 1.16-3.28; p < 0.05). According to UALCAN database, breast cancer, ovarian cancer, colon cancer and lung adenocarcinoma display an elevated SP1 expression in comparison with normal tissues. Kaplan-Meier survival plots indicate SP1 mRNA level has negative effects on prognosis of liver hepatocellular carcinoma and brain lower grade glioma.Conclusion: SP1 was associated with lymph node metastasis, TNM stage and depth of invasion, and indicated poor clinical outcome, which brought new insights on the potential candidacy of SP1 in clinical usage.

Download Full-text

Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis

Disease Markers ◽

10.1155/2016/8137378 ◽

2016 ◽

Vol 2016 ◽

pp. 1-9 ◽

Cited By ~ 9

Author(s):

Shanshan Huang ◽

Jiawei Zheng ◽

Yufang Huang ◽

Li Song ◽

Yin Yin ◽

...

Keyword(s):

Pancreatic Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Meta Analysis ◽

Clinicopathological Characteristics ◽

Node Metastasis ◽

Relative Risks ◽

Potential Marker ◽

S100a4 Expression ◽

The Relationship

Background.The small Ca2+-binding protein S100A4 is identified as a metastasis-associated or metastasis-inducing protein in various types of cancer. The goal of this meta-analysis was to evaluate the relationship between S100A4 expression and clinicopathological characteristics and prognosis of patients with pancreatic cancer.Methods. A comprehensive literature search was carried out in the electronic databases PubMed and Chinese CNKI. Only the studies reporting the correlation between S100A4 expression and clinicopathological characteristics or overall survival (OS) of patients with pancreatic cancer are enrolled. Extracted data was analyzed using the RevMan 5.3 software to calculate the pooled relative risks (95% confidence interval, CI) for statistical analyses.Results.Seven studies including a total of 474 patients were enrolled into this meta-analysis. Negative expression of S100A4 was significantly associated with higher 3-year OS rate (RR = 3.92, 95% CI = 2.24–6.87,P<0.0001), compared to S100A4-positive cases. Moreover, negative expression of S100A4 was also related to N0 stage for lymph node metastasis (RR = 2.15, 95% CI = 1.60–2.88,P<0.0001). However, S100A4 expression was not significantly correlated with histological types and distant metastasis status.Conclusion.S100A4 expression represents a potential marker for lymph node metastasis of pancreatic cancer and a potential unfavorable factor for prognosis of patients with this disease.

Download Full-text

The Prognostic and Clinicopathological Significance of LASP1 Expression in Cancer Patients: Systematic Review and Meta-Analysis

10.21203/rs.3.rs-257500/v1 ◽

2021 ◽

Author(s):

Jian Luo ◽

Yuanzhi Zhu ◽

Ying Long ◽

Fei Huang ◽

Xiaozou Luo ◽

...

Keyword(s):

Gastric Cancer ◽

Lung Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Cancer Patients ◽

Distant Metastasis ◽

Meta Analysis ◽

Tnm Stage ◽

Node Metastasis ◽

T Classification

Abstract Background Many cancer researchers have investigated the prognostic significance of LASP1 for survival of patients with various types of cancer. Nevertheless, the role LASP1 palyed in cancer prognosis remains unknown. In consequence, we carried out this study in order to comprehensively analyze the prognostic value of LASP1 in cancer patients. Methods A systematical research was conducted in electronic databases, such as PubMed, Embase and Web of Science. Eighteen studies meeting the inclusion criteria were enrolled. Overall survival (OS), recurrence-free survival (RFS) and various clinicopathological parameters were used as the endpoints in this study. Results A total of 2023 cancer patients from eighteen studies were finally enrolled into our meta-analysis. The results revealed that the cancer patients with high expression of LASP1 exhibited shorter OS (HR = 2.04, 95%CI = 1.77–2.34, P < 0.01) and RFS (HR = 2.11, 95%CI = 1.51–2.95, P < 0.01) than those with low expression of LASP1, and patients whose tumors expressed high LASP1 had shorter OS in lung cancer (HR = 2.20, 95%CI = 1.45–3.36, P < 0.01) and gastric cancer (HR = 1.64, 95%CI = 1.14–2.36, P < 0.01) respectively. Furthermore, the cancer patients whose tumors expressed high LASP1 were apparently associated with advanced TNM stage (OR = 2.92, 2.27–3.76, P < 0.01), earlier lymph node metastasis (OR = 2.69, 1.62–4.45, P < 0.01), advanced T classification (OR = 2.17, 1.48–3.18, P < 0.01) and earlier distant metastasis (OR = 2.56, 1.03–6.35, P = 0.04) when compared to those whose tumors expressed low LASP1. Conclusions Our study showed that the high LASP1 expression might be an undesirable predictor for patients with various types of cancers in the aspect of OS, RFS, TNM stage, lymph node metastasis, T classification and distant metastasis, and the high LASP1 expression might be an undesirable predictor for lung cancer patients and gastric cancer patients. Therefore, the expression of LASP1 might be utilized as a novel indicator in judging the prognosis of cancer patients, especially in lung cancer and gastric cancer.

Download Full-text

Clinicopathological Significance of Neuropilin 1 Expression in Gastric Cancer: A Meta-Analysis

Disease Markers ◽

10.1155/2020/4763492 ◽

2020 ◽

Vol 2020 ◽

pp. 1-8

Author(s):

Hui Cao ◽

Yan Li ◽

Limin Huang ◽

Banjun Bai ◽

Zhong Xu

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Size ◽

Early Stage ◽

Meta Analysis ◽

Group Versus ◽

Tnm Stage ◽

Node Metastasis ◽

Neuropilin 1

Background. Neuropilin 1 (NRP1) is involved in tumorigenesis, development, invasion, and metastasis by promoting angiogenesis of tumors. The study is aimed at evaluating the correlation between the expression of NRP1 protein and clinicopathological features of gastric cancer by meta-analysis. Methods. The published studies were searched in databases including CNKI, Wanfang, Chongqing VIP, Web of Science, and PubMed online. Clinical case studies were included to compare the correlation between NRP1 protein expression and clinicopathological characteristics of gastric cancer. The quality of the included literatures was evaluated by NOS scale. Meta-analysis was performed by Stata software to calculate the odds ratio (OR) and 95% confidence interval (CI). Results. A total of 12 studies were included in this analysis, involving 1,225 patients with gastric cancer. The analysis indicated that the expression of NRP1 protein in gastric cancer tissues was lower in the group of early stage versus advanced stage (OR=0.128, 95%CI=0.059−0.277, P≤0.001), tumor size less than 5 cm versus more than 5 cm (OR=0.443, 95%CI=0.310−0.632, P≤0.001), TNM stage I-II group versus stage III-IV patients (OR=0.736, 95%CI=0.589−0.919, P=0.007), well to medium differentiation group versus poor differentiation group (OR=0.735, 95%CI=0.632−0.854, P≤0.001), and nonlymph node metastasis group versus lymph node metastasis group (OR=0.667, 95%CI=0.522−0.854, P≤0.001). The expression of NRP1 protein in gastric cancer was not related to gender, age, and Laurèn’s classification. Conclusion. The expression of NRP1 protein in gastric cancer is closely correlated to clinical stage, tumor size, TNM stage, differentiation, and lymph node metastasis.

Download Full-text

LncRNA AWPPH as a Prognostic Predictor in Human Cancers: Evidence From Meta-analysis

10.21203/rs.3.rs-121126/v1 ◽

2020 ◽

Author(s):

Yongfeng Li ◽

Xinmiao Rui ◽

Daobao Chen ◽

Haojun Xuan ◽

Hongjian Yang ◽

...

Keyword(s):

Overall Survival ◽

Lymph Node ◽

Lymph Node Metastasis ◽

Tumor Size ◽

Vascular Invasion ◽

Meta Analysis ◽

Clinicopathological Features ◽

Tnm Stage ◽

Node Metastasis ◽

Human Cancers

Abstract Background: Long noncoding RNA associated with poor prognosis of hepatocellular carcinoma (AWPPH) is a novel oncogene and dysregulated in a variety of human cancers. It has been revealed to be associated with the clinicopathological features and prognosis. However, the prognostic value of AWPPH in various cancers remains unclear. Therefore, we perform this meta-analysis to evaluate the relationship between AWPPH expression and clinical outcomes in human cancers.Methods: Comprehensive literature search was performed in PubMed, Web of Science, CNKI and Wangfang databases, and eligible studies were obtained according to the inclusion and exclusion criteria. The pooled hazard ratios (HRs) and odds ratios (ORs) were applied to assess the clinical value of AWPPH expression for overall survival (OS) and clinicopathological features.Results: A total of 19 articles including 1699 cancer patients were included in the study. The pooled results demonstrated that evaluated AWPPH expression was positively related to a poorer overall survival of patients with cancers (HR=1.79, 95%CI: 1.44-2.14, P<0.001). Subgroup analysis revealed that tumor type and sample size affect the predictive value of AWPPH on OS, whereas cut-off value and HR estimation method have no impact on it. In addition, the pooled data also showed that AWPPH was positively linked to advanced TNM stage (OR=2.67, 95%CI: 1.86-3.83, P<0.001) , bigger tumor size (OR=2.64, 95%CI:1.47-4.73, P=0.001), macro-vascular invasion (OR=2.08, 95%CI: 1.04-4.16, P=0.04) and lymph node metastasis (OR=2.68, 95%CI: 1.82-3.96, P<0.001). Moreover, the results of the trim and fill analysis confirmed the reliability of our finding. Conclusions: Upregulation of AWPPH was associated with advanced TNM stage, bigger tumor size, worse lymph node metastasis, macro-vascular invasion, and shorter overall survival, suggesting that AWPPH may serve as a biomarker for prognosis and clinicopathological characteristics in human cancers.

Download Full-text

The Differences Between Multifocal and Unifocal Papillary Thyroid Carcinoma in Unilateral Lobe: A Meta-Analysis

Frontiers in Oncology ◽

10.3389/fonc.2021.657237 ◽

2021 ◽

Vol 11 ◽

Author(s):

Ting Zhang ◽

Liang He ◽

Zhihong Wang ◽

Wenwu Dong ◽

Wei Sun ◽

...

Keyword(s):

Lymph Node ◽

Lymph Node Metastasis ◽

Meta Analysis ◽

Clinical Manifestations ◽

Tnm Stage ◽

Central Lymph Node ◽

Lateral Lymph Node ◽

Central Lymph Node Dissection ◽

Node Metastasis ◽

Central Lymph

BackgroundAs many inconsistent reports on the clinical manifestations and prognosis between unilateral unifocal PTC (UUPTC) and unilateral multifocal PTC (UMPTC), identifying the difference should guide management. The purpose of this study was to investigate other additional differences between UUPTC and UMPTC in addition to their difference in the number of cancer foci.Data SourcesA systematic literature search was conducted in the PubMed and Web of Science databases for relevant studies published before December 31, 2020. Their reference lists were also reviewed.Review MethodsTwo reviewers independently extracted data and assessed the quality of eligible studies. Studies on patients who underwent an open thyroidectomy with or without neck dissection were included. Data were analyzed using the RevMan 5.3 software.ResultsFifteen studies comprising 9,665 patients were selected for the meta-analysis. UMPTC occurred in 10% to 36% of all PTC cases. There were no significant differences between UMPTC and UUPTC patients in age, gender, tumor size, and extrathyroidal extension (ETE). However, significant differences (P < 0.05) between UMPTC and UUPTC patients were observed in central lymph node metastasis (CLNM), lateral lymph node metastasis (LLNM), tumor-node-metastasis (TNM) stage I+II, TNM stage III+IV, the recurrence/persistence of the UMPTC group after total thyroidectomy and overall recurrence/persistence.ConclusionUMPTC patients are more likely to have CLNM, LLNM, more advanced TNM stage, and recurrence/persistence than UUPTC patients. Compared with UUPTC, UMPTC patients should undergo central lymph node dissection, and pay more attention to LLNM, TNM stage and recurrence/persistence during the follow-up.

Download Full-text